Overview
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Status:
Completed
Completed
Trial end date:
2006-06-01
2006-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the efficacy, safety, and pharmacoeconomics of treatment with subcutaneous (SC) epoetin beta (NeoRecormon) in participants with hematologic malignancies or solid tumors. The anticipated time on study treatment is 20 weeks, and the target sample size is 60 individuals.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Epoetin Alfa
Criteria
Inclusion Criteria:- Adults at least 18 years of age
- Multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), chronic lymphocytic
leukemia (CLL), breast cancer, lung cancer, or ovarian cancer
- Anemia with low erythropoeitin (EPO) levels
Exclusion Criteria:
- Poorly controlled hypertension
- Relevant acute or chronic bleeding requiring therapy within 3 months before study drug
- Treatment with EPO within the last 6 weeks
- Pregnant or breastfeeding females